Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.Aduhelm (Drug), Alzheimer’s Disease, Food and Drug Administration, Drugs (Pharmaceuticals), Labeling and Labels (Product), Clinical Trials, Elderly, Science and Technology, Regulation and Deregulation of Industry, Research, Brain, Biogen Inc, your-feed-science, your-feed-healthcareRead More
